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Pediatric patients with relapsed/refractory (R/R) mature B-
cell non-Hodgkin lymphoma (B-NHL) have a 2-year
overall survival rate with chemoimmunotherapy (CIT) of
15–33% [1, 2]. Rituximab plus ifosfamide, carboplatin, and
etoposide (RICE) is widely used in R/R children with NHL
[3] and rituximab plus vincristine, ifosfamide, carboplatin,
idarubicin, and dexamethasone (RVICI) has been used in
Europe [4, 5].
In preclinical studies, ibrutinib, a Bruton’s tyrosine
kinase inhibitor approved to treat adults with various B-cell
malignancies in the United States and the European Union,
among other countries [6], inhibited Burkitt lymphoma (BL;
the predominant pediatric mature B-NHL) and diffuse large
B-cell lymphoma (DLBCL) tumor cell growth, and pro-
longed survival in BL xenografted mice [7–10].
We report safety, pharmacokinetics, and preliminary
efficacy findings from the run-in stage (part 1; December
2016–December 2018) of an ongoing phase 3 trial
(SPARKLE).
Of 21 patients with mature B-NHL (median age, 8 years
[range, 3–17]; Table 1), 11 received ibrutinib plus modified
RICE (RICE modified with dexamethasone) and 10
received ibrutinib plus RVICI (Supplementary Fig. 1).
Detailed methods are presented in the Supplementary
Appendix, and Supplementary Tables 1 and 2 show the
dosing and administration schedule for these treatment
regimens. In ibrutinib plus modified RICE and ibrutinib
plus RVICI groups, respectively, zero and four (40.0%)
patients had central nervous system (CNS) disease, three
(27.3%) and four (40.0%) had bone marrow involvement,
and one (9.1%) and six (60.0%) received >1 prior line of
therapy (>1 relapse).
In ibrutinib plus modified RICE and ibrutinib plus
RVICI groups, respectively, median number of treatment
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cycles was 3.0 (range, 1–4) and 2.0 (range, 1–4), and eight
and three patients completed ≥3 cycles (Supplementary
Fig. 1).
Despite limitations of cross-trial comparisons, including
small patient numbers and trial design differences, safety of
combined therapies was consistent with known ibrutinib,
RVICI, or RICE safety profiles and experience with ibrutinib
plus RICE or rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone in adults with DLBCL [11]. All
patients had 1 or more grade ≥3 treatment-emergent adverse
events (TEAEs), with >50% of patients in either group
having hematologic, gastrointestinal, infectious, and meta-
bolism- or nutrition-associated events (Supplementary
Table 3). Ten (90.9%) patients in ibrutinib plus modified
RICE and nine (90.0%) in ibrutinib plus RVICI groups had
serious TEAEs (all grade ≥3). Most frequent grade ≥3
ibrutinib-related TEAEs (i.e., those considered related by the
investigator) were thrombocytopenia (42.9%), neutropenia
(38.1%), anemia (33.3%), and febrile neutropenia (19.0%;
Supplementary Table 4).
Two patients in ibrutinib plus modified RICE and three
in ibrutinib plus RVICI groups had major hemorrhage
events (grade 3/4; in the setting of thrombocytopenia;
Supplementary Table 5). Two major hemorrhage events
(intestinal and intracranial) in the ibrutinib plus RVICI arm
were considered ibrutinib related. Major hemorrhage has
occurred in 4% of 2838 ibrutinib-exposed patients in 27
previous clinical trials [12].
Hematologic TEAEs were expected, particularly with
background CIT. In a study of 20 children with R/R B-NHL
receiving RICE alone, rituximab-related AEs, infections,
and hematologic toxicities (e.g., neutrophil- and platelet-
related events) occurred frequently, and one child dis-
continued because of prolonged myelosuppression [1].
As expected with the CIT regimen [1], bone marrow
suppression, reported as laboratory abnormality of low
hemoglobin, platelets, or neutrophils, was common (Sup-
plementary Appendix). Hematologic events were generally
manageable, most recovering before the next cycle without
delaying treatment.
Pharmacokinetic data were assessed for <12 years
and ≥12 years. For patients aged 12–17 years (n= 6), area
under plasma concentration–time curves (AUCs) were
within target range (250–1500 ng × h/mL), supporting the
329 mg/m2/day dose (not exceeding 560 mg daily). How-
ever, in younger patients (n= 14), AUCs at 329 mg/m2/day
were lower than expected, and 440 mg/m2/day was required
to obtain exposures mostly within target range (Fig. 1). No
AUC values were >1500 ng × h/mL regardless of age or
dose. AUC value on cycle 1 day 7 was notably lower than
day 1.
Although treatment was scheduled to avoid overlapping
ibrutinib and mesna dosing, this was not always possible
given prolonged mesna infusion during days 3–9 with
RVICI. Mass spectrometric and radiometric analysis of
14C-labeled ibrutinib and mesna, or ifosfamide with meta-
bolizing enzymes, did not show ibrutinib adduct formation
or decreased ibrutinib concentrations. Inter- and intraindi-
vidual AUC value variability occurred and exceeded
variability in adults. Inter-sample discrepancies were
potentially introduced by cytochrome P450 subtype 3A
inhibitors/inducers (one patient used CYP3A inhibitor, one
used CYP3A inducer) before/during ibrutinib treatment
(considered a study protocol deviation), ibrutinib
Table 1 Patient demographics and baseline characteristics.
Ibrutinib plus
modified RICE
(n= 11)
Ibrutinib plus RVICI
(n= 10)
Median age (range), years 11.0 (3–17) 8.0 (4–15)
Age group, years, n (%)
1–5 2 (18.2) 2 (20.0)
6–11 4 (36.4) 6 (60.0)
12–17 5 (45.5) 2 (20.0)
Sex, n (%)
Female 3 (27.3) 1 (10.0)
Male 8 (72.7) 9 (90.0)
Ethnicity, n (%)
Hispanic or Latino 2 (18.2) 0
Not Hispanic or Latino 6 (54.5) 9 (90.0)
Unknown 1 (9.1) 0
Not reported 2 (18.2) 1 (10.0)
Race, n (%)
White 9 (81.8) 10 (100.0)
Asian 1 (9.1) 0
Not reported 1 (9.1) 0
Time from initial diagnosis to first dose of study drug (months)
Mean (SD) 11.7 (10.94) 10.5 (6.22)
Median (range) 7.0 (4–37) 8.2 (5–25)
Type of mature B-cell NHL at initial diagnosis, n (%)
Burkitt-like lymphoma 2 (18.2) 1 (10.0)
Burkitt lymphoma 4 (36.4) 3 (30.0)
Burkitt leukemia 2 (18.2) 4 (40.0)
Diffuse large B-cell
lymphoma
3 (27.3) 0
Primary mediastinal B-
cell lymphoma
0 1 (10.0)
High-grade B-cell
lymphoma
0 1 (10.0)
Other 0 0
Extra nodal sites, n (%)
Central nervous system 0 4 (40.0)
Bone marrow 3 (27.3) 4 (40.0)
Other 9 (81.8) 9 (90.0)
Prior lines of therapy, n (%)
1 10 (90.9) 4 (40.0)
>1 1 (9.1) 6 (60.0)
NHL non-Hodgkin lymphoma, SD standard deviation, modified RICE
rituximab, ifosfamide, carboplatin, and etoposide, with the addition of
dexamethasone, RVICI vincristine, ifosfamide, carboplatin, idarubicin,
that includes dexamethasone.
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administration via nasogastric tube in some patients, or time
and content of food intake differences pre- and post-
ibrutinib administration.
Physiology-based pharmacokinetic simulations using an
adult ibrutinib model [13] suggested body surface
area–based dosing would result in adult range exposures
(Loeckie de Zwart, May 28, 2015, unpublished data).
Although the youngest patient was almost 4 years old, a
predicted increase in patients aged <6 years was uncorro-
borated. Exposures were still at the low end of the target
range, but above observed minimum exposure in adults at
560 mg/day (shown as efficacious in adult B-cell
malignancies).
In the ibrutinib plus modified RICE group, there were
three progressive disease (PD)-related deaths (one of which
was due to multiple organ failure within 30 days of the last
dose) and one AE (septic shock)-related death within
30 days of the last dose occurred. In the ibrutinib plus
RVICI group, three TEAE-related deaths (unrelated to
ibrutinib; within 30 days of last dose; two due to sepsis and
one because of neutropenic sepsis) and six PD-related
deaths occurred. Most of these patients had multiply
relapsed disease and were heavily pretreated pre-enroll-
ment; therefore, they had poor hematologic reserve and
were highly susceptible to complications due to therapy.
Preliminary efficacy findings were promising. As prog-
nosis for this pediatric patient population is poor, achieving
a complete response (CR) to proceed to high-dose con-
solidative therapy is important [1]. Of 21 patients who
received ≥1 dose of ibrutinib, 12 (57.1%) experienced a
response. In the ibrutinib plus modified RICE group, eight
(72.7%) were responders, among whom three (27.3%) had a
CR, including one unconfirmed CR (one DLBCL, one BL,
one Burkitt leukemia [B-AL]), and five (45.5%) had a
partial response (PR; one BL, two DLBCL, two Burkitt-like
lymphoma). In the ibrutinib plus RVICI group, four
(40.0%) were responders, among whom two (20%) had a
CR (both B-AL) and two had a PR (one B-AL, one high-
grade B-cell lymphoma). Across both groups, all responders
received treatment at first relapse, except one with high-
grade B-cell lymphoma in the ibrutinib plus RVICI arm
who achieved PR in second relapse.
Among 14 patients treated after first relapse, 11 (78.6%)
were responders (five CR, six PR), and one of seven
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Fig. 1 Ibrutinib exposures
with 240–440 mg/m2/day
doses. Box/whisker plots of
estimated AUC on
pharmacokinetic occasions by
cycle and day for each dose for
(a) AUCτ (estimated AUC of
24-h dosing interval) and (b)
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represents median, box
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represent 10/90% confidence
interval. Individual symbols
represent outliers. (c) AUCτ
versus age and (d) versus body
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represent individual patients,
color represents dose, and
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Target AUC range based
on adult exposures was
250–1500 ng × h/mL. AUC
area under the plasma
concentration–time curve.
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(14.3%) treated after second relapse was a responder (one
PR). Supplementary Table 6 presents response by histology.
Although this part of the study was not designed to compare
efficacy of either regimen, overall response and CR rates
were higher with ibrutinib plus RICE than ibrutinib plus
RVICI. At an 18-month median follow-up, median
investigator-assessed event-free survival (EFS) was
unreached in the ibrutinib plus modified RICE group and
2.4 months in the ibrutinib plus RVICI group (Supple-
mentary Fig. 2), potentially because more patients treated
with the latter had received >1 prior line of therapy.
Treatment at first relapse (versus second relapse) was
associated with a higher response rate and longer EFS
possibly because patients tolerated therapy better and did
not discontinue prematurely due to AEs. In addition, unlike
those in the ibrutinib plus RICE group, some patients in the
ibrutinib plus RVICI arm had CNS involvement, and
therefore a poorer overall prognosis. Given the exploratory
nature of the EFS analysis and small sample size, it is dif-
ficult to ascertain whether the addition of ibrutinib to CIT is
beneficial and results should be interpreted with caution.
Seven patients subsequently received hematopoietic stem
cell transplantation (HSCT; four in the ibrutinib plus
modified RICE group and two in the ibrutinib plus RVICI
arm after completing ≥3 treatment cycles, and one after
completing two cycles of ibrutinib plus RVICI and one
cycle of ibrutinib monotherapy; Supplementary Fig. 1).
Results of part 1 of the trial support the continued
assessment of ibrutinib with modified RICE/RVICI in this
patient population. Part 2 is assessing the efficacy of ibru-
tinib (329 mg/m2/day in patients aged ≥12 years and 440
mg/m2/day in patients aged <12 years) plus modified RICE/
RVICI versus modified RICE/RVICI CIT alone in a ran-
domized fashion. Pharmacokinetic sampling in part 2 is on
day 15 instead of day 7 of cycle 1 to avoid potential
interactions. Because preliminary efficacy findings were
better in patients treated upon first relapse, the protocol was
amended to only include patients in first relapse. Due to the
very poor prognosis for pediatric patients with R/R mature
B-NHL, trials such as this, while challenging to conduct, are
critically important.
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